W. Wainberg, Ten big challenges ahead, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1
DOI : 10.1186/1471-2334-14-S2-S1

R. Gulick, New ARV drugs, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.2
DOI : 10.1186/1471-2334-14-S2-S2

M. Boffito, Development of long-acting ARVs, BMC Infect Dis, vol.2014, issue.14 2, p.11

. Nelson, First Line Therapy in 2014, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.3
DOI : 10.1186/1471-2334-14-S2-S3

N. Clumeck, C. Mwamba, K. Kabeya, C. Vincent, M. Serge et al., First-line therapy with LPV/r vs NVP and 2 NRTIs in a developing country: W144 of a randomized trial, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1402
DOI : 10.1186/1471-2334-14-S2-O2

F. Miedema, M. Hazenberg, K. Tesselaar, D. Van-baarle, R. De-boer et al., Immune Activation and Collateral Damage in AIDS Pathogenesis, Frontiers in Immunology, vol.4, 2013.
DOI : 10.3389/fimmu.2013.00298

P. Mallon, Aging with HIV, Current Opinion in HIV and AIDS, vol.9, issue.4, pp.428-435
DOI : 10.1097/COH.0000000000000080

B. Peters, ARV regimen choice and co-morbidities, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.9
DOI : 10.1186/1471-2334-14-S2-S9

URL : http://doi.org/10.1186/1471-2334-14-s2-s9

K. Lichtenstein, Statin use in setting of HIV infection, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.10
DOI : 10.1136/bmj.f2610

S. Hussen, K. Andes, D. Gilliard, R. Chakraborty, D. Rio et al., Transition to Adulthood and Antiretroviral Adherence Among HIV-Positive Young Black Men Who Have Sex With Men, American Journal of Public Health, vol.105, issue.4, pp.1-7, 2014.
DOI : 10.2105/AJPH.2014.301905

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358185

M. Cohen, ART for prevention: opportunities, challenges and predictions, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.7
DOI : 10.1186/1471-2334-14-S2-S7

URL : http://doi.org/10.1186/1471-2334-14-s2-s7

J. Lange, Implementation of TasP: challenges and opportunities, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.8
DOI : 10.1186/1471-2334-14-S2-S8

L. Shan, Update on HIV reservoirs, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.18
DOI : 10.1186/1471-2334-14-S2-S18

T. Rasmussen, M. Tolstrup, A. Winckelmann, L. Østergaard, and O. Søgaard, Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials, Human Vaccines & Immunotherapeutics, vol.6, issue.4, pp.790-799
DOI : 10.4161/hv.23202

J. Lutzen, Gene therapy and bone marrow transplantation, BMC Infect Dis, vol.2014, issue.14 2, p.19

J. Hauber, J. Karpinski, I. Iauber, J. Chemnitz, H. Hofmann-sieber et al., Next-generation LTR-specific Tre-recombinase targets a majority of HIV-1 isolates, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.14018
DOI : 10.1186/1471-2334-14-S2-O18

A. Gatignol, R. Scarborough, M. Levesque, E. Boudrias-dalle, C. Chutei et al., Towards gene therapy against HIV-1: new therapeutic target in gag RNA accessible to ribozymes and RNA interference molecules, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.14019
DOI : 10.1186/1471-2334-14-S2-O19

L. Czernekova, M. Raska, Z. Moldoveanu, K. Zachova, S. Hall et al., Differential glycosylation of envelope gp120 affects reactivity with HIV-1 specific antibodies, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1468
DOI : 10.1186/1471-2334-14-S2-P68

M. Girard, Is an HIV vaccine achievable?, BMC Infect Dis, vol.2014, issue.14 2, p.14

S. Rerks-ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu et al., Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand, New England Journal of Medicine, vol.361, issue.23, pp.3612209-2220, 2009.
DOI : 10.1056/NEJMoa0908492

R. Bailer, E. Crooks, A. Cupo, A. Druz, N. Garrett et al., Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies, Nature, vol.509, pp.55-62, 2014.

B. Su and C. Moog, Which antibody functions are important for an HIV vaccine? Front Immunol, p.289, 2014.

A. Padane, M. Camara, M. Seydi, W. Jennes, A. Diallo et al., Resistance to HIV-1 infection among HIV-exposed seronegative partners in HIV-discordant couples is associated with higher frequency of CD8+ T cells expressing CD107a and b molecules, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1467
DOI : 10.1186/1471-2334-14-S2-P67

S. Hua, C. Lecuroux, A. Saez-cirion, G. Pancino, I. Girault et al., The potential role of HIV-specific CD38-/HLA-DR+ CD8+ T cells in viral suppressive activity and cytotoxicity in HIV controllers, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1464
DOI : 10.1186/1471-2334-14-S2-P64

URL : https://hal.archives-ouvertes.fr/inserm-00995736

L. Hauber, J. Schulze-zur-wiesch, U. Schuhmacher, C. Schäfer, J. Van-lunzen et al., Personalizing humanized mice with cells obtained from an HIV post treatment controller, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1436
DOI : 10.1186/1471-2334-14-S2-P36

L. Stamatatos, L. Morris, D. Burton, and J. Mascola, Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?, Nature Medicine, vol.453, issue.8, pp.866-870, 2009.
DOI : 10.1038/nm.1949

A. West, . Jr, L. Scharf, J. Scheid, F. Klein et al., Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy, Cell, vol.156, issue.4, pp.633-648, 2014.
DOI : 10.1016/j.cell.2014.01.052

R. Slavcev, S. Nafissi, and N. , Optimized production of a safe and efficient gene therapeutic vaccine versus HIV via a linear covalently closed DNA minivector, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.74
DOI : 10.1186/1471-2334-14-S2-P74

M. Selbovitz and D. Miller, In vivo analysis of GenePro, a lentivral therapeutic vaccine, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.2
DOI : 10.1186/1471-2334-14-S2-P2

C. Bauche, M. Rodriguez, E. Sarry, A. Bejanariu, and E. Sabbah-petrover, Lentiviral-based anti-HIV therapeutic vaccine: design, preclinical studies and phaseI/II clinical trial preliminary results, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.1481
DOI : 10.1186/1471-2334-14-S2-P81

A. Caruso, M. Laria, F. Caccuri, C. Giagulli, and S. Fiorentini, Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study, BMC Infect Dis, vol.2014, issue.2, pp.14-20

A. Balazs, Y. Ouyang, C. Hong, J. Chen, S. Nguyen et al., Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission, Nature Medicine, vol.20, issue.3, pp.296-300, 2014.
DOI : 10.1038/nm1431

D. Zagury, J. Bernard, A. Halbreich, B. Bizzini, C. Carelli et al., One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: a new strategy, J Acquir Immune Defic Syndr, vol.5, issue.7, pp.676-681, 1992.

Y. Guan, M. Pazgier, M. Sajadi, R. Kamin-lewis, S. Al-darmarki et al., Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding, Proceedings of the National Academy of Sciences, vol.110, issue.1, pp.69-78
DOI : 10.1073/pnas.1217609110

T. Asselah and P. Marcellin, Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow, Liver International, vol.141, issue.Suppl 1, pp.88-102
DOI : 10.1111/j.1478-3231.2011.02699.x

R. Schinazi, P. Halfon, P. Marcellin, and T. Asselah, HCV direct-acting antiviral agents: the best interferon-free combinations, Liver International, vol.15, issue.Suppl, pp.69-78
DOI : 10.1111/liv.12423

P. Halfon and P. Cacoub, Prise en charge th??rapeutique de l???h??patite??C ?? l???heure des agents antiviraux directs??: vers une ??radication virale, La Revue de M??decine Interne, vol.35, issue.4, pp.219-221, 2014.
DOI : 10.1016/j.revmed.2013.12.017

E. Feeney and R. Chung, Antiviral treatment of hepatitis C, BMJ, vol.349, issue.jul07 3, p.3308
DOI : 10.1136/bmj.g3308

J. Rockstroh, Managing HCV infection: present and future, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.5
DOI : 10.1186/1471-2334-14-S2-S5

F. Zoulim, New anti-HCV agents in the pipeline, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.15
DOI : 10.1186/1471-2334-14-S2-S15

URL : https://hal.archives-ouvertes.fr/inserm-00995744

V. Soriano, Treatment of hepatitis C in HIV patients in the new DAA era, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.16
DOI : 10.1186/1471-2334-14-S2-S16

F. Simon, J. Ferraro, E. Javelle, and C. Marimoutou, Chikungunya infection: six years after, rheumatic morbidity and impaired quality of life persist!, BMC Infectious Diseases, vol.14, issue.Suppl 2, p.21
DOI : 10.1186/1471-2334-14-S2-O21

E. Javelle, A. Ribera, I. Degasne, C. Marimoutou, and F. Simon, Clinical spectrum of post-chikungunya rheumatic musculoskeletal disorders and use of disease-modifying antirheumatic drugs to treat the chronic inflammatory entities: 6-year experience from Reunion Island, BMC Infectious Diseases, vol.14, issue.Suppl 2, pp.14-20
DOI : 10.1186/1471-2334-14-S2-O20